http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019503423-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-522 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-739 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-095 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H15-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-22 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-095 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08B37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-739 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04 |
| filingDate | 2017-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2019503423-A |
| titleOfInvention | Modified tetraacylated Neisseria LPS |
| abstract | The present invention relates to a Neisseria LPS having a tetraacylated lipid A moiety, wherein the tetraacylated lipid A moiety lacks one of the secondary acyl chains compared to the lipid A moiety of wild type Neisseria LPS; And is modified in that it lacks the primary acyl chain at position 3 of glucosamine located at the reducing end of the lipid A moiety. The invention further relates to a Neisseria bacterium that has been genetically modified to reduce the expression of one of the endogenous lpxL1 or lpxL2 genes and introduce the expression of a heterologous pagL gene. The Neisseria LPS of the present invention has TLR4 agonist properties and is therefore useful in compositions that elicit or stimulate an immune response, such as a vaccine, as well as other forms of immunotherapy. [Selection figure] None |
| priorityDate | 2016-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 941.